52,318$
-5,51%
Echtzeit-Aktienkurs Crinetics Pharmaceuticals
Bid:
Ask:
Echtzeit-Chart der Crinetics Pharmaceuticals Aktie
Börsenkurse Crinetics Pharmaceuticals
| Tradegate | - | - | - | - | 50,050€ | -5,12% |
| Börse Stuttgart | - | - | - | - | 52,000€ | -1,42% |
| USA | - | - | - | - | 52,090$ | -5,92% |
| Nasdaq | - | - | - | - | 52,070$ | -5,96% |
| Echtzeit USD | - | - | - | - | 52,318$ | -5,51% |
| Echtzeit Euro | - | - | - | - | 50,250€ | -2,90% |
| Lang & Schwarz | - | - | - | - | 50,400€ | -4,91% |
| Börse Frankfurt | - | - | - | - | 50,250€ | -2,43% |
| gettex | - | - | - | - | 50,250€ | -4,74% |
Fundamentaldaten der Crinetics Pharmaceuticals Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 4,01 Mio. | -214,53 Mio. | -214,53 Mio. | -3,69 | - | - | 888,80 |
| 2022 [USD] | 4,74 Mio. | -163,92 Mio. | -163,92 Mio. | -3,15 | - | - | 595,05 |
| 2021 [USD] | 1,08 Mio. | -107,64 Mio. | -107,64 Mio. | -2,80 | - | - | 2310,00 |
| 2020 [USD] | - | -73,81 Mio. | -73,81 Mio. | -2,42 | - | - | - |
| 2019 [USD] | - | -50,42 Mio. | -50,42 Mio. | -2,09 | - | - | - |
| 2018 [USD] | - | -27,12 Mio. | -27,12 Mio. | -2,23 | - | - | - |
| 2017 [USD] | - | -9,16 Mio. | -9,16 Mio. | -0,38 | - | - | - |
| 2016 [USD] | - | -6,02 Mio. | -6,02 Mio. | -0,25 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Crinetics Pharmaceuticals Aktie
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.